Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 16/20 | 0.69 |
| ▸ | RARB | P10826 | 16/20 | 0.69 |
| ▸ | RARG | P13631 | 16/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.69 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.69 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.44 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6294021 | 1.00 | RARA (0.69) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6292573 | 0.87 | RARB (0.50) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8557713 | 0.86 | RARA (0.52) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293941 | 0.83 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6816008 | 0.83 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6293940 | 0.83 | RARA (0.64) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6705630 | 0.83 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8557715 | 0.83 | RARA (0.48) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8772575 | 0.83 | RARA (0.68) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755036 | 0.82 | RARA (1.00) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855832-B2 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-6818775-B2 | TREATMENT OF SKIN-RELATED DISEASES OR PREVENTION OF CERTAIN UNDESIRED SIDE EFFECTS OF ADMINISTERED RETINOIDS | ALLERGAN, INC. | 2004-11-16 | — | — | US | disclosed |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | JOHNSON ALAN T (US) | 2004-07-01 | — | — | US | disclosed |
| EP-0915825-B1 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN INC (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6720425-B2 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6653483-B1 | Skin, neurodegenerative and cardiovascular disorders; anticarcinogenic, antiinflammatory, and antiproliferative agents | ALLERGAN, INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-10-02 | — | — | US | disclosed |
| US-6555690-B2 | 4-((5,5-dimethyl-5,6,7,8-tetrahydro-8-hydroxynaphthalen-2 -yl)carbonyloxy)benzoic acid, benzyl ester for example; receptor subtype selectivity for side effect reduction | ALLERGAN, INC. | 2003-04-29 | — | — | US | disclosed |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-11-21 | — | — | US | disclosed |
| US-6465663-B2 | ETHYL (E)-4-(2-(5,6-DIHYDRO-5,5-DIMETHYL-NAPHTHALEN-8(7H)-ONE-2 -YL)ETHENYL)BENZOATE AND ETHYL (E)-4-(2-(5,6-DIHYDRO-5,5-DIMETHYL-8-(PHENYLTHIO)-NAPHTHALENYL)ETHENYL) BENZOATE | ALLERGAN, INC. | 2002-10-15 | — | — | US | disclosed |
| US-20020099038-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2002-07-25 | — | — | US | disclosed |
| US-6344561-B2 | TREATMENT OF SKIN DISORDERS, INFLAMMATION, NERVE SYSTEM DISORDERS, CANCER | ALLERGAN SALES, INC. | 2002-02-05 | — | — | US | disclosed |
| US-20010000511-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | ALLERGAN, INC. | 2001-04-26 | — | — | US | disclosed |
| US-6187933-B1 | BIND TO RETINOID RECEPTORS; TREATING SKIN DISORDERS | ALLERGAN SALES, INC. | 2001-02-13 | — | — | US | disclosed |
| US-6117987-A | ANIMAL GROWTH REGULATOR; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | ALLERGAN SALES, INC. (US) | 2000-09-12 | — | — | US | disclosed |
| US-6051731-A | TREATING SKIN DISORDERS, CANCERS, EYE DISORDERS, CARDIOVASCULAR DISORDERS, ELIMINATE OR REDUCE SIDE EFFECTS OF RETINOIDS, OR TO TREAT RETINOID OR VITAMIN A OVERDOSE OR POISONING | ALLERGAN SALES, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-5998655-A | SKIN DISORDERS; ANTICANCER AGENTS | ALLERGAN, INC. | 1999-12-07 | — | — | US | disclosed |
| EP-0915825-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | Allergan Sales, Inc. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997048672-A2 | SUBSTITUTED TETRAHYDRONAPHTHALENE AND DIHYDRONAPHTHALENE DERIVATIVES HAVING RETINOID AND/OR RETINOID ANTAGONIST-LIKE BIOLOGICAL ACTIVITY | ALLERGAN SALES, INC. (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187235-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20020099038-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20010000511-A1 | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20030078440-A1 | O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20040127469-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
| US-20020173631-A1 | Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity | RARB, RARA, RXRB | RARA 2/4885RARB 1/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.